Diphosphonates in the evaluation of metabolic bone disease.
The bone scan may be of value in the assessment of patients with metabolic bone disease. However the superiority of the bone scan when compared to radiology in conditions such as renal osteodystrophy, osteomalacia, primary hyperparathyroidism, and osteoporosis requires substantiation with the newer radiopharmaceuticals which have a higher affinity for bone. Two methods of quantitating skeletal uptake of tracer have been assessed to try to remove the subjective aspect of bone scan evaluation. Measurements of bone to soft tissue ratios have proved clinically disappointing, but 24 hour whole body retention of diphosphonate appears to provide a sensitive index of increased bone turnover.
D001851:Bone Diseases, Metabolic / Q000000981:diagnostic imaging*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000000981:diagnostic imaging; D004164:Diphosphonates; D012968:Etidronic Acid; D006801:Humans; D006980:Hyperthyroidism / Q000000981:diagnostic imaging; D015609:Organotechnetium Compounds; D010018:Osteomalacia / Q000000981:diagnostic imaging; D010024:Osteoporosis / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate
D004164:Diphosphonates; D015609:Organotechnetium Compounds; C019561:technetium Tc 99m etidronate; D013667:Technetium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate